Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK Adaptimmune gains full control of late-stage preclinical optimized PRAME [….]
Cell therapies have grown to become a prevailing field dominating new medical breakthroughs with the promise of treatments and cures for multiple diseases. The biopharma hubs of Philadelphia and Maryland have emerged as important drivers of this new wave of medicine, build on the foundation of renowned research institutes, universities, and a number of successful cell therapy companies who have paved the way forward in this field.
We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.
Philadelphia, the birthplace of cell and gene therapy, is home to a number of companies focused on developing multiple treatment options for rare diseases, those that affect less than 200,000 people in the United States.
For decades, the United States and the United Kingdom have enjoyed a special relationship that crosses political, economic, and military lines. But, the two nations also share a similar comradery in the Life Sciences arena, and prominent biotech hubs like the BioHealth Capital Region and Philadelphia showcase that connection.
